Key regions: France, Europe, United Kingdom, Brazil, India
The demand for oncology drugs in EU-27 has been steadily increasing over the years due to various factors.
Customer preferences: One of the main reasons for the growth in the oncology drugs market is the aging population in Europe. As people age, the risk of developing cancer increases, leading to a higher demand for oncology drugs. Additionally, the rise in cancer cases has resulted in a greater need for advanced treatments and therapies. Patients are now seeking more targeted and personalized treatments that offer better outcomes and fewer side effects.
Trends in the market: The oncology drugs market in EU-27 has seen a shift towards immunotherapies and targeted therapies. These treatments have shown promising results in treating various types of cancer, including lung, breast, and skin cancer. Another trend in the market is the development of biosimilars, which are cheaper alternatives to biologic drugs. The rise of biosimilars has led to increased competition and lower prices for oncology drugs.
Local special circumstances: Each country in EU-27 has its own unique circumstances that affect the oncology drugs market. For example, Germany has a strong healthcare system that provides access to innovative treatments, leading to a higher demand for oncology drugs. On the other hand, countries like Greece and Portugal have faced economic challenges that have impacted their ability to invest in healthcare, leading to a lower demand for oncology drugs.
Underlying macroeconomic factors: The oncology drugs market in EU-27 is also influenced by macroeconomic factors such as government policies and regulations. The European Medicines Agency (EMA) plays a crucial role in regulating the approval and marketing of oncology drugs in the region. Additionally, the increasing cost of drug development and the pressure to lower drug prices have led to changes in the way oncology drugs are priced and reimbursed. In conclusion, the oncology drugs market in EU-27 is driven by factors such as the aging population, the need for advanced treatments, and the rise of immunotherapies and biosimilars. However, each country in the region has its own unique circumstances that affect the demand for oncology drugs. The market is also influenced by macroeconomic factors such as government policies and regulations.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
